ID CLB HC.PH.BIO.CLB
Develops drugs, biologics or cell and gene therapies with no approved product on the market (no revenue, or milestones only); such a developer is here, not in contract research.
Sector, group and industry above this class, as placed in the current release. The sector and the industry link to their companies.
Companies whose primary class this is. The sector and industry pages and the screener count them the same way.
| Company | Ticker | Country | Market cap | Filings |
|---|---|---|---|---|
| Revolution Medicines, Inc. | RVMD | United States of America | $38.71B | 899 |
| Summit Therapeutics Inc. | SMMT | United States of America | $10.53B | 603 |
| Ascendis Pharma A/S | ASND | Denmark | $15.60B | 811 |
| BridgeBio Pharma, Inc. | BBIO | United States of America | $14.40B | 901 |
| Regencell Bioscience Holdings Ltd | RGC | United States of America | $11.92B | 85 |
| ABIVAX | ABVX | France | $11.71B | 1,092 |
| Praxis Precision Medicines, Inc. | PRAX | United States of America | $9.36B | 547 |
| Abivax S.A. | ABVX | United States of America | $12.19B | 103 |
| Vaxcyte, Inc. | PCVX | United States of America | $8.44B | 794 |
| Nuvalent, Inc. | NUVL | United States of America | $9.74B | 609 |
| ARROWHEAD PHARMACEUTICALS, INC. | ARWR | United States of America | $8.09B | 1,370 |
| CYTOKINETICS INC | CYTK | United States of America | $11.57B | 2,528 |
| Kymera Therapeutics, Inc. | KYMR | United States of America | $9.82B | 733 |
| Arcellx, Inc. | ACLX | United States of America | $6.73B | 452 |
| BELITE BIO, INC | BLTE | Cayman Islands | $6.58B | 267 |
| Protagonist Therapeutics, Inc | PTGX | United States of America | $7.99B | 731 |
| Apogee Therapeutics, Inc. | APGE | United States of America | $6.81B | 349 |
| Centessa Pharmaceuticals plc | CNTA | United Kingdom | $6.27B | 626 |
| Terns Pharmaceuticals, Inc. | TERN | United States of America | $6.12B | 469 |
| CG Oncology, Inc. | CGON | United States of America | $6.21B | 261 |
| Celcuity Inc. | CELC | United States of America | $4.31B | 591 |
| Scholar Rock Holding Corp | SRRK | United States of America | $5.65B | 712 |
| Xenon Pharmaceuticals Inc. | XENE | Canada | $5.00B | 867 |
| Cogent Biosciences, Inc. | COGT | United States of America | $5.52B | 652 |
| Erasca, Inc. | ERAS | United States of America | $5.76B | 377 |
| CALIWAY BIOPHARMACEUTICALS CO., LTD. | 6919 | Taiwan | $5.30B | 737 |
| Immunovant, Inc. | IMVT | United States of America | $7.30B | 664 |
| CRISPR Therapeutics AG | CRSP | Switzerland | $5.79B | 906 |
| Dianthus Therapeutics, Inc. | DNTH | United States of America | $4.44B | 680 |
| Spyre Therapeutics, Inc. | SYRE | United States of America | $7.67B | 837 |
| Viking Therapeutics, Inc. | VKTX | United States of America | $4.02B | 680 |
| NewAmsterdam Pharma Co N.V. | NAMS | Netherlands | $3.60B | 456 |
| Edgewise Therapeutics, Inc. | EWTX | United States of America | $3.58B | 456 |
| Structure Therapeutics Inc. | GPCR | United States of America | $3.06B | 294 |
| Zealand Pharma | ZEAL | Denmark | $3.09B | 1,654 |
| Dyne Therapeutics, Inc. | DYN | United States of America | $3.92B | 818 |
| Tango Therapeutics, Inc. | TNGX | United States of America | $4.65B | 444 |
| Oruka Therapeutics, Inc. | ORKA | United States of America | $5.32B | 1,465 |
| IDEAYA Biosciences, Inc. | IDYA | United States of America | $2.49B | 550 |
| Vera Therapeutics, Inc. | VERA | United States of America | $2.88B | 496 |
| Denali Therapeutics Inc. | DNLI | United States of America | $2.87B | 844 |
| ALUMIS INC. | ALMS | United States of America | $3.79B | 267 |
| Arcus Biosciences, Inc. | RCUS | United States of America | $3.64B | 650 |
| SOLENO THERAPEUTICS INC | SLNO | United States of America | $2.76B | 1,129 |
| ASCENTAGE PHARMA GROUP INTERNATIONAL | AAPG | United States of America | $2.62B | 127 |
| Celldex Therapeutics, Inc. | CLDX | United States of America | $2.65B | 1,296 |
| Immunome Inc. | IMNM | United States of America | $2.64B | 480 |
| Beam Therapeutics Inc. | BEAM | United States of America | $2.47B | 557 |
| Maze Therapeutics, Inc. | MAZE | United States of America | $2.36B | 229 |
| Disc Medicine, Inc. | IRON | United States of America | $2.91B | 807 |
Other names for this activity, and where neighboring activities go instead.
preclinicaldrug developer
Research-led company whose approved medicines, which it discovered, are in one or two therapeutic areas; it moves to Branded Prescription Drugs only after two consecutive annual reports with approved products in three or more.
https://financialfilings.com/oics/CLB/
This page is keyed by the class ID CLB. IDs are assigned in v0.3 and freeze at v1.0; from then on an ID is never renamed or reused, and if the class moves in the tree, its ID and this URL stay the same.
Sign in or create a free account - no password needed.
By continuing, you agree to our Terms and Privacy Policy.